Orphan Drug Fairness Act

Summary

Orphan Drug Fairness Act This bill amends the Patient Protection and Affordable Care Act (PPACA) to exclude sales of any drug or biological product approved by the Food and Drug Administration solely for rare diseases or conditions (orphan drug) from the calculation of the annual fee on manufacturers or importers with branded prescription drug sales exceeding $5 million. This Act is effective as if included in PPACA.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 30 July 2015

   Introduced

   Read twice and referred to the Committee on Finance.

   Source: IntroReferral

2. 30 July 2015

   Introduced

   Introduced in Senate

   Source: IntroReferral

Votes

No vote records are attached yet.

Versions

• Introduced in Senate · 30 July 2015 · Official file

Documents

3 official files

• Introduced in Senate (text)

  Introduced in Senate · EN · 30 July 2015

  ViewDownloadOpen at official source

• Introduced in Senate (PDF)

  Introduced in Senate · EN · 30 July 2015

  ViewDownloadOpen at official source

• Introduced in Senate

  summary · EN · 30 July 2015

  Open at official source

Sponsors

• Sen. Menendez, Robert [D-NJ] · D · Sponsor
• Mike Crapo · R · Sponsor
• · ssfi00 · Standing

Related records

• related to ← Orphan Drug Fairness Act